Core Viewpoint - *ST Tianmao (000627.SZ) announced its decision to voluntarily terminate its stock listing on the Shenzhen Stock Exchange and will apply to transfer to the National Equities Exchange and Quotations (NEEQ) after delisting [1] Group 1: Company Actions - The company convened its 10th Board of Directors' fourth meeting to approve the proposal for voluntary delisting [1] - The stock is set to resume trading on August 11, 2025, after the termination of its listing [1] Group 2: Financial Status and Risks - *ST Tianmao is currently facing a delisting crisis due to its failure to disclose the 2024 annual report and the 2025 Q1 report within the legal timeframe [4] - The company has not disclosed its financial reports as of August 6, 2024, and is working to complete the necessary documentation [4] - As of the end of Q3 2024, *ST Tianmao has over 120,000 shareholders [5] Group 3: Company Background - *ST Tianmao operates as an investment holding company primarily engaged in insurance business through its subsidiaries, Guohua Life and Huari Insurance [5] - Guohua Life, established in November 2007, has total assets of 271.599 billion and net assets of 26.22 billion as of June 2023 [5]

Core Viewpoint - Vincerx Pharma, Inc. is set to delist its common stock from Nasdaq due to non-compliance with listing rules, with trading suspended and plans for liquidation announced [2][3][4]. Group 1: Delisting and Trading Suspension - Vincerx received a delisting notice from Nasdaq on April 14, 2025, due to its common stock closing bid price being below the minimum requirement of $1.00 per share for 30 consecutive business days [2]. - Trading of Vincerx's common stock will be suspended at the opening of business on April 23, 2025, and the company intends to file a Form 25 Notification of Delisting with the SEC around April 28, 2025 [1][2]. - An inadvertent suspension of trading occurred on April 16, 2025, but trading will resume on April 21, 2025, until April 22, 2025 [4]. Group 2: Company Actions and Future Plans - The board of directors has decided to dissolve, liquidate, and wind up the company's affairs, distributing any remaining assets to stockholders after settling debts [3]. - Vincerx does not plan to appeal Nasdaq's determination and will not seek to list its common stock on another exchange [3]. - Following the effectiveness of Form 25, Vincerx will file a Form 15 to deregister with the SEC [4]. Group 3: Company Background - Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, with a research facility in Monheim, Germany [5].